LL-37 Dosage Guide: Antimicrobial Protocols, Wound Healing, and Lyme Disease

LL-37 is the only known human cathelicidin — a class of host defense peptides (HDPs) that serve as front-line components of the innate immune system. Unlike antibiotics, which directly kill bacteria, LL-37 works by disrupting microbial membranes, modulating immune responses, and promoting tissue repair simultaneously. This multi-modal mechanism has made LL-37 a subject of intense research for applications ranging from wound care to chronic infection management.

LL-37 is produced naturally by neutrophils, macrophages, epithelial cells, and NK cells in response to infection, injury, or vitamin D signaling. Its natural roles include direct antimicrobial defense, immune cell recruitment, wound healing facilitation, and anti-biofilm activity — the last being of particular interest in chronic infection scenarios like Lyme disease.

Mechanism of Action

LL-37 operates through several distinct and complementary pathways:

Membrane disruption: LL-37's cationic amphipathic structure allows it to insert into and disrupt microbial cell membranes, killing bacteria, fungi, and some viruses directly. This membrane-targeting action is effective against both gram-positive and gram-negative bacteria and, critically, against organisms in biofilm states that resist conventional antibiotics.

Immune modulation: LL-37 is a potent chemoattractant for neutrophils, monocytes, and dendritic cells. It activates TLR signaling to initiate innate immune responses while also modulating inflammatory cytokines to prevent excessive tissue damage — a balance that is critical in wound healing and chronic infection management.

Angiogenesis promotion: LL-37 stimulates the formation of new blood vessels (angiogenesis) through VEGF-dependent and independent pathways. This makes it a significant player in wound closure and tissue regeneration.

Epithelial barrier repair: LL-37 promotes keratinocyte migration and proliferation, accelerating re-epithelialization in wound healing.

Anti-biofilm activity: LL-37 is one of the few known agents capable of disrupting established biofilms — the protective matrix that allows persistent bacteria like Borrelia (Lyme) and Pseudomonas to resist antibiotic treatment.

Standard Dosage Range

LL-37 is used exclusively via subcutaneous injection in peptide therapy contexts. There is no validated oral form, and intranasal use is experimental (though some topical wound care formulations are in development).

• Low dose: 50 mcg per injection
• Standard dose: 100 mcg per injection
• Frequency: Daily to every other day, depending on indication
• Route: Subcutaneous, typically abdominal fat or outer thigh

Doses above 100 mcg per injection are not standard practice; LL-37 has potent immunomodulatory and cell-signaling effects that do not benefit from high-dose escalation in the same way some other peptides do.

Antimicrobial Protocol

For general antimicrobial support — including prevention during immunosuppressive states, adjunct to antibiotic therapy, or management of recurrent infections:

• Dose: 50–100 mcg subcutaneous, daily
• Duration: 2–4 weeks for acute antimicrobial support; ongoing at 3x weekly for chronic immune support
• Pairing: Commonly used alongside Thymosin Alpha-1 for enhanced T-cell and innate immune coverage

LL-37's broad-spectrum antimicrobial activity covers:

• Gram-negative bacteria (E. coli, Pseudomonas aeruginosa, Klebsiella)
• Gram-positive bacteria (Staphylococcus aureus including MRSA, Streptococcus)
• Fungi (Candida albicans)
• Viruses (influenza, HSV, rhinovirus — in vitro activity)

Clinical applications being investigated include topical LL-37 for chronic wound biofilms, nebulized LL-37 for cystic fibrosis lung infections, and systemic LL-37 for sepsis adjunct therapy.

Wound Healing Protocol

For accelerating wound healing in non-healing wounds, post-surgical recovery, diabetic ulcers, and burns:

• Dose: 50–100 mcg subcutaneous, daily or every other day
• Injection site: Near the wound perimeter (perilesional subQ injection); systemic abdominal injection also produces wound effects but local injection may concentrate activity
• Duration: Until wound closure or plateau in healing; typically 2–6 weeks
• Pairing with BPC-157: BPC-157 and LL-37 are complementary for wound healing — BPC-157 drives fibroblast activity and collagen production while LL-37 manages biofilm burden and promotes angiogenesis

Research in diabetic wound models shows LL-37 accelerates wound closure rates significantly, particularly in the re-epithelialization and angiogenesis phases. This is clinically significant because diabetic wounds often fail precisely in these phases due to impaired LL-37 production (a consequence of hyperglycemia suppressing cathelicidin expression).

Lyme Disease and Chronic Infection Protocol

Borrelia burgdorferi, the bacterium responsible for Lyme disease, is notorious for its ability to form antibiotic-resistant biofilms — spirochete colonies encased in a protective extracellular matrix that conventional antibiotics cannot penetrate effectively. This biofilm formation is believed to be a primary driver of persistent Lyme symptoms (Post-Treatment Lyme Disease Syndrome).

LL-37 is among the few agents with demonstrated anti-Borrelia biofilm activity in laboratory research. Studies show LL-37 can:

• Disrupt established Borrelia biofilms
• Kill persister cells within biofilm communities
• Prevent biofilm formation at sub-inhibitory concentrations

Lyme co-infection protocol (used in integrative medicine settings):

• Dose: 100 mcg subcutaneous, daily
• Duration: 4–8 weeks as adjunct to antibiotic therapy; some practitioners use ongoing 3x weekly protocols in persistent Lyme
• Pairing: Thymosin Alpha-1 for immune support, BPC-157 for gut and tissue repair from long-term antibiotic use
• Monitoring: Herxheimer reactions (temporary worsening of symptoms due to bacterial die-off) are possible when starting LL-37 in active Lyme; start at 50 mcg and titrate upward

The evidence base for LL-37 in Lyme disease is currently limited to in vitro and animal studies. No human clinical trials have been completed. However, the mechanistic rationale is strong, and its use in integrative Lyme protocols is increasing among practitioners working with treatment-refractory patients.

See also: Peptides for Lyme Coinfections for a broader overview of the peptide toolkit in chronic Lyme management.

LL-37 in Inflammatory Conditions

LL-37 plays a complex, context-dependent role in inflammation. At physiological levels, it resolves inflammation by promoting M2 macrophage polarization and clearing apoptotic debris. However, at elevated levels (as seen in psoriasis and some autoimmune conditions), LL-37 can amplify inflammation by activating plasmacytoid dendritic cells.

For therapeutic use in inflammatory conditions, this duality means:

• LL-37 is generally beneficial in immunosuppressive or infection-driven inflammatory states (HIV, Lyme, chronic fatigue)
• LL-37 may be contraindicated or require caution in autoimmune inflammatory conditions (psoriasis, lupus, certain arthritides) where it has been shown to participate in disease pathogenesis

Vitamin D and LL-37

One of the most clinically actionable findings in LL-37 research is its dependence on vitamin D for natural production. The cathelicidin gene (CAMP, which encodes LL-37) contains a vitamin D response element in its promoter region — meaning adequate vitamin D levels directly drive LL-37 production in immune cells and epithelium.

Vitamin D deficiency significantly impairs endogenous LL-37 production, which is believed to partially explain the increased infection susceptibility seen with vitamin D deficiency. For users pursuing LL-37 peptide therapy, ensuring vitamin D sufficiency (serum 25-OH-D ideally above 50 ng/mL) maximizes both endogenous and therapeutic LL-37 activity.

Side Effects and Safety

LL-37 is naturally produced in the human body and its exogenous administration appears well-tolerated at research doses:

• Injection site reactions: The most common side effect; mild redness, warmth, or discomfort at subQ injection sites
• Herxheimer reactions: In active infection contexts (particularly Lyme), temporary symptom worsening as bacteria die; typically brief (24–72 hours) and managed by starting at lower doses
• Inflammatory flares: In individuals with underlying inflammatory or autoimmune conditions, LL-37 can theoretically amplify ongoing inflammation; use with caution and monitoring
• Systemic effects: At research doses, significant systemic side effects are not commonly reported

LL-37 has not been studied in long-term human clinical trials for the indications described here. Its safety profile is extrapolated from short-term research and the fact that it is an endogenous human peptide.

Frequently Asked Questions

Q: What is LL-37 used for in research? Current research focuses on: topical wound healing formulations, nebulized delivery for cystic fibrosis lung infections, anti-biofilm applications in device-related infections, and systemic use in sepsis and chronic infection. Its role in vitamin D-mediated immunity is also an active area.

Q: Can LL-37 replace antibiotics? No. LL-37 is a complement to, not a replacement for, antibiotic therapy. Its anti-biofilm and immunomodulatory properties may enhance the effectiveness of antibiotics by disrupting biofilm protection and improving immune cell function, but it does not have the bacterial killing power at therapeutic doses to substitute for antibiotics in acute infection.

Q: How is LL-37 different from other antimicrobial peptides? LL-37 is unique in being the only human cathelicidin. Many antimicrobial peptides (AMPs) are from animal or plant sources. LL-37's human origin and its involvement in immune modulation, angiogenesis, and tissue repair makes it more versatile than simple antimicrobial peptides.

Q: Does LL-37 need to be refrigerated? Yes. Lyophilized LL-37 powder should be stored frozen (−20°C) for long-term storage or refrigerated for short-term use. Once reconstituted in bacteriostatic water, keep refrigerated and use within 2–3 weeks.

Q: Can LL-37 be used alongside antibiotics? Yes, and this is the standard approach in protocols targeting biofilm-forming bacteria. LL-37's biofilm-disrupting activity exposes bacteria to antibiotics that would otherwise be unable to penetrate the biofilm matrix, making the antibiotic more effective.

Q: Is LL-37 safe for people with autoimmune conditions? Caution is warranted. LL-37 has been implicated in the pathogenesis of psoriasis and lupus, where elevated LL-37 activates inflammatory cascades. For individuals with these conditions, LL-37 supplementation could theoretically worsen disease. Medical consultation is essential before use.